Tracking a new cell therapy for hard-to-treat blood cancer in adults

This is a real-world study watching how Inaticabtagene Autoleucel Injection performs in adults with relapsed or refractory B-cell acute lymphoblastic leukemia — a serious blood cancer that has either returned after treatment or is no longer responding to standard therapy. Researchers will track how well the medication works and how safe it is when used in everyday clinical practice. This is not a randomized trial where some patients get the drug and others don't; instead, doctors will treat eligible patients with this medication and researchers will carefully observe and record the results.

While this treatment has already been approved for use, doctors and researchers want to understand how it performs in real patients outside of controlled clinical trials, and to gather more information about its long-term safety and effectiveness.